Compare CRNX & ESNT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CRNX | ESNT |
|---|---|---|
| Founded | 2008 | 2008 |
| Country | United States | Bermuda |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Property-Casualty Insurers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.9B | 5.9B |
| IPO Year | 2018 | 2013 |
| Metric | CRNX | ESNT |
|---|---|---|
| Price | $35.26 | $56.91 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 9 | 7 |
| Target Price | ★ $74.78 | $67.86 |
| AVG Volume (30 Days) | ★ 903.6K | 674.0K |
| Earning Date | 05-07-2026 | 05-08-2026 |
| Dividend Yield | N/A | ★ 2.42% |
| EPS Growth | N/A | ★ 0.73 |
| EPS | N/A | ★ 6.90 |
| Revenue | $1,039,000.00 | ★ $1,260,935,000.00 |
| Revenue This Year | $722.66 | N/A |
| Revenue Next Year | $183.79 | $3.18 |
| P/E Ratio | ★ N/A | $8.40 |
| Revenue Growth | N/A | ★ 1.45 |
| 52 Week Low | $24.10 | $51.61 |
| 52 Week High | $57.99 | $67.09 |
| Indicator | CRNX | ESNT |
|---|---|---|
| Relative Strength Index (RSI) | 26.12 | 34.09 |
| Support Level | $33.23 | $56.84 |
| Resistance Level | $37.23 | $57.32 |
| Average True Range (ATR) | 1.50 | 1.04 |
| MACD | -0.01 | -0.06 |
| Stochastic Oscillator | 3.41 | 10.99 |
Crinetics Pharmaceuticals Inc is a commercial-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its main product, Palsonify (paltusotine), is a once-daily, oral treatment approved by the FDA for adults with acromegaly who have had an inadequate response to surgery and/or for whom surgery is not an option. Additionally, the company's development pipeline includes several programs, including a late-stage investigational candidate, atumelnant, currently in development for CAH and ADCS, and CRN09682, a NDC candidate that is being developed to treat SST2-expressing NETs and other SST2-expressing solid tumors.
Essent Group Ltd serves the housing finance industry by providing private mortgage insurance, reinsurance, risk management products, title insurance, and settlement services to mortgage lenders, borrowers, and investors to support homeownership. It provides credit protection to lenders and mortgage investors by covering a portion of the unpaid principal balance of a mortgage and certain related expenses in the event of a default. By providing capital to mitigate mortgage credit risk, the company allows lenders to make additional mortgage financing available to prospective homeowners.